Nerac

Information That Drives Innovation

We’re here to help with your research needs
+1 860 872 7000
Customer Access
  • Home
  • What We Do
    • Innovation Insights and Consulting Practice
    • Regulatory
    • Medical Device and Life Sciences
    • Technology Scouting and Innovation
    • Market Research
    • Intellectual Property
    • Commercialization Services for TTOs and Start-Ups
    • Critical Updates
  • Who We Serve
  • How to Engage
  • Why Nerac?
  • Meet our Team
    • Leadership Team
    • Our Analysts
    • Our Partners
  • Nerac Insights and Publications
    • Articles
    • Case Studies
    • Press Room
    • Videos
    • Webcasts
    • White Papers
  • Contact Us
You are here: Home / Nerac Insights / Nerac Announces the May Issue of the Nerac Strategist

Nerac Announces the May Issue of the Nerac Strategist

Facebook0
Google+0
LinkedIn0
Twitter0

New release offers in-depth business perspectives on industry issues, compliance challenges and commercial opportunities authored by Nerac analysts, industry experts

Read the full release here.

Related Posts

  • Is Carbon Fiber on Your Horizon? 3D Print It.
    53
    By Rosemarie Szostak, Ph.D., Nerac Analyst, Originally Published: April 27, 2017 Carbon fiber has been incorporated into everything from tennis rackets to airplanes. It increases the strength and stiffness of structural parts without adding weight. Unfortunately, carbon fiber itself is not cheap to produce. A new tool for the carbon fiber toolbox is 3D printing.…
    Tags: fiber, carbon, printing, published, originally, nerac, read
  • The Importance of Article Selection for Meeting the MedDev 2.7.1 Rev 3 Requirements
    47
    By Donna Mitchell-Magaldi, Nerac Analyst, On March 20, 2010, the revised Guideline; MedDev 2.7.1 Rev 3 Clinical Evaluation: A Guide for Manufacturers and Notified Bodies became a requirement for obtaining and maintaining a CE Mark for all classes of devices marketed in the European Union. An important component of the MedDev 2.7.1 Rev 3 is the…
    Tags: rev, device, read, full, nerac, medical
  • Modest Impact on Personalized Medicine Expected from Recent SCOTUS Rulings
    47
    By Roz Sweeney, Ph.D. Nerac Analyst, The recent Supreme Court decision on the Association for Molecular Pathology v. Myriad Genetics case was the culmination of much litigation on the validity of patent protection for the genomic sequences of BRCA1 and BRCA2. Myriad Genetics’ patents on these two genes gave it the exclusive right to offer genetic…
    Tags: read, full, nerac, medicine, device, medical
  • Case Studies
  • White Papers
  • Webcasts
  • Articles
    • Nerac Strategist
    • Energy
    • Food & Nutrition
    • Intellectual Property
    • Regulatory
    • Technology & Innovation
    • Medical Device & Healthcare
    • Pharmaceutical
    • Engineering
    • Market Research
    • Critical Alerts
    • Chemistry/Advanced Materials
  • Press Room

Click here to learn more about….

3d printing advanced materials aerospace Ask Kevin Videos biotech CFDA clinical literature evaluations commercialization strategies competitive intelligence Disruptive Technologies emerging markets energy EU MDR FDA food helga weires Industry 4.0 innovation Inspiring Next intellectual property intellectual property strategies IP market analysis market research medical device medical devices nerac Nerac client questions Nerac Strategist notified body audit open innovation Order 650 patenting strategies patent landscape pharmaceutical Post-Market Surveillance R&D regulatory regulatory compliance Robert Beinstein Rosemarie Szostak specialty chemicals Sustainable Development Goals technology scouting XcellR8
  • Facebook
  • Google+
  • LinkedIn
  • RSS
  • Twitter
  • YouTube
  • Career Opportunities
  • Privacy Policy

Copyright © 2022 Nerac · One Technology Drive · Tolland, CT 06084 · 1.860.872.7000

Sign Up for the Nerac Strategist

Like what you see? Sign up here to receive the Nerac Strategist newsletter, a compilation of analyst insights on rapidly developing industry issues, compliance challenges and commercial opportunities!
  • This field is for validation purposes and should be left unchanged.